Effectiveness and Safety of Omalizumab in Patients with Allergic Bronchopulmonary Aspergillosis with or Without Allergic Rhinitis: a Retrospective Chart Review

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2023 Oct 13

PMID 37833657

Authors

Cuihong Cai

Jingjing Qu

Jianying Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Omalizumab is a valuable alternative treatment for allergic bronchopulmonary aspergillosis (ABPA). The effectiveness and safety of this medication have not been confirmed. The main purpose of this study was to evaluate the effectiveness and safety of omalizumab for ABPA.

Methods: This study involved a retrospective chart review. The main indicators used were asthma control test (ACT) scores, lung function parameters, doses of corticosteroids, acute exacerbation, hospitalization rates, total serum immunoglobulin E (IgE) levels, and blood eosinophil counts. Related adverse events were also reviewed to evaluate the safety of omalizumab.

Results: Fourteen patients with ABPA were included, of whom 10 (71%) concurrently had allergic rhinitis (AR). There were improvements in the mean percentages of the forced vital capacity, percentages of the forced expiratory volume in 1 s, and ACT score after omalizumab administration (p < 0.05, p < 0.01, and p < 0.01, respectively). After the initiation of omalizumab administration, the median corticosteroid dose, acute exacerbation rate, hospitalization rate, and mean blood eosinophil count decreased when compared with the baseline values (p < 0.05, p < 0.05, p < 0.01, and p < 0.05, respectively). A reduction in the total serum IgE level was observed in patients with ABPA without AR compared with that in patients with AR (p < 0.05). One patient reported a concurrent skin rash, which spontaneously resolved without medication.

Conclusion: It is safe and effective to prescribe omalizumab to patients with ABPA, irrespective of whether they have AR. Dose adjustment of omalizumab is safe after disease control. The total serum IgE level might be a predictor of the effectiveness of omalizumab in patients without AR.

Citing Articles

Allergic Bronchopulmonary Aspergillosis/Mycosis: An Allergic Disease or an Eosinophilic Disease?.

Asano K, Oguma T Intern Med. 2024; 64(4):493-501.

PMID: 39231658 PMC: 11904459. DOI: 10.2169/internalmedicine.4386-24.

References

Agarwal R, Aggarwal A, Dhooria S, Sehgal I, Garg M, Saikia B . A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2015; 47(2):490-8. DOI: 10.1183/13993003.01475-2015. View

Asano K, Kamei K, Hebisawa A . Allergic bronchopulmonary mycosis - pathophysiology, histology, diagnosis, and treatment. Asia Pac Allergy. 2018; 8(3):e24. PMC: 6073182. DOI: 10.5415/apallergy.2018.8.e24. View

Moss R . The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. Ann N Y Acad Sci. 2012; 1272:49-57. DOI: 10.1111/j.1749-6632.2012.06810.x. View

Tomomatsu K, Oguma T, Baba T, Toyoshima M, Komase Y, Taniguchi M . Effectiveness and Safety of Omalizumab in Patients with Allergic Bronchopulmonary Aspergillosis Complicated by Chronic Bacterial Infection in the Airways. Int Arch Allergy Immunol. 2020; 181(7):499-506. DOI: 10.1159/000507216. View

Sehgal I, Agarwal R . Pulse methylprednisolone in allergic bronchopulmonary aspergillosis exacerbations. Eur Respir Rev. 2014; 23(131):149-52. PMC: 9487262. DOI: 10.1183/09059180.00004813. View

Humbert M, Busse W, Hanania N, Lowe P, Canvin J, Erpenbeck V . Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014; 2(5):525-36.e1. DOI: 10.1016/j.jaip.2014.03.010. View

Tillie-Leblond I, Germaud P, Leroyer C, Tetu L, Girard F, Devouassoux G . Allergic bronchopulmonary aspergillosis and omalizumab. Allergy. 2011; 66(9):1254-6. DOI: 10.1111/j.1398-9995.2011.02599.x. View

Ma Y, Zhang W, Yu B, Chen Y, Mu S, Cui Y . [Prevalence of allergic bronchopulmonary aspergillosis in Chinese patients with bronchial asthma]. Zhonghua Jie He He Hu Xi Za Zhi. 2012; 34(12):909-13. View

Rosenberg M, Patterson R, Mintzer R, COOPER B, Roberts M, Harris K . Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977; 86(4):405-14. DOI: 10.7326/0003-4819-86-4-405. View

10.

Corren J, Casale T, Deniz Y, Ashby M . Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003; 111(1):87-90. DOI: 10.1067/mai.2003.49. View

11.

Li J, Fan L, Li M, Cao W, Xu J . Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature. Respir Med. 2016; 122:33-42. DOI: 10.1016/j.rmed.2016.11.019. View

12.

Perisson C, Destruys L, Grenet D, Bassinet L, Derelle J, Sermet-Gaudelus I . Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis. Respir Med. 2017; 133:12-15. DOI: 10.1016/j.rmed.2017.11.007. View

13.

Denning D, Pleuvry A, Cole D . Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2012; 51(4):361-70. DOI: 10.3109/13693786.2012.738312. View

14.

Agarwal R, Dhooria S, Sehgal I, Aggarwal A, Garg M, Saikia B . A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. Chest. 2018; 153(3):656-664. DOI: 10.1016/j.chest.2018.01.005. View

15.

Korkmaz E, Aydin O, Mungan D, Sin B, Demirel Y, Bavbek S . Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?. Eur Ann Allergy Clin Immunol. 2022; 56(1):26-33. DOI: 10.23822/EurAnnACI.1764-1489.261. View

16.

Aydin O, Celebi Sozener Z, Soyyigit S, Kendirlinan R, Gencturk Z, Misirligil Z . Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center's experience with 14 cases. Allergy Asthma Proc. 2015; 36(6):493-500. DOI: 10.2500/aap.2015.36.3909. View

17.

Bleecker E, Menzies-Gow A, Price D, Bourdin A, Sweet S, Martin A . Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. Am J Respir Crit Care Med. 2019; 201(3):276-293. PMC: 6999108. DOI: 10.1164/rccm.201904-0903SO. View

18.

El-Qutob D . Off-Label Uses of Omalizumab. Clin Rev Allergy Immunol. 2015; 50(1):84-96. DOI: 10.1007/s12016-015-8490-y. View

19.

Wark P, Hensley M, Saltos N, Boyle M, Toneguzzi R, Epid G . Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol. 2003; 111(5):952-7. DOI: 10.1067/mai.2003.1388. View

20.

Wark P, Hussaini S, Holder C, Powell H, Gibson P, Oldmeadow C . Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization. J Allergy Clin Immunol Pract. 2020; 8(10):3428-3433.e1. DOI: 10.1016/j.jaip.2020.05.055. View